The combination therapy of hyperthermia and chemotherapy regimens for the treatment of non-small cell lung cancer: A meta-analysis

Objective:To evaluate the effectiveness and safety of hyperthermia combined with chemotherapy for non-small cell lung cancer(NSCLC).Methods:All of randomized controlled trials(RCT)about hyperthermia in combination with chemotherapy(versus chemotherapy alone)were collected through Cochrane library,PubMed,EMbase,CBM,CNKI,VIP,Wanfang Database from database inception to October 2019,no limit on language.Two researchers extracted data and assess literature quality separately,and made a meta-analysis by RevMan 5.3 software.32 trials with 2361 patients,1154 in treatment group and 1152 in control group,wereincluded in the review.Results:The results of the Meta-analysis exhibited that compared with chemotherapy alone,hyperthermia combined with chemotherapy could can enhance tumor response rate[RR=1.48,95%CI(1.34,1.63),p<0.01],improve the quality of life[RR=1.67,95%CI(1.46,1,91),p<0.01];one year survival rate[RR=1.43,95%CI(1.22,1.68),p<0.01];reduce the gastrointestinal reactions[RR=0.82,95%CI(0.68,0.98),p<0.05].Meanwhile there was no significant difference in the incidence of severe myelosuppression between the two groups:WBC toxicity[RR=0.74,95%CI(0.48,1.13),p=0.16],Platelet toxicity[RR=1.24,95%CI(0.65,2.39),p=0.52].Conclusion:The results showed that for the treatment of NSCLC,the addition of hyperthermia to chemotherapy can increase the long-term and short-term effects of chemotherapy,improve the quality of life of patients,and did not significantly increase the incidence of myelosuppression.More high quality and large-scale randomized controlled trials are required in the future.